Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals, Inc.

INOVIO Pharmaceuticals is a clinical-stage biotechnology company focused on developing DNA medicines to fight HPV-related diseases, cancer, and infectious diseases. The company uses proprietary technology to design DNA plasmids for targeted treatments.

Metric
Company Name	Inovio Pharmaceuticals, Inc.
Symbol	INO
MSH ID	COM:INOVIO
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	122
Website	inovio.com
LinkedIn
Founders

Metric
Market Cap	240.45M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	832.01K
Revenue (LTM)
Revenue (NTM)
Gross Profit	-2.67M
EBITDA	-131.72M
Operating Income	-135.23M
Net Income	-135.12M
EPS	-6.09
Diluted EPS	-6.09
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.98
Operating Profit Margin	-173.00
EBITDA Margin	-158.32
Net Profit Margin	3.43K
Return on Equity	18.29
Return on Assets	16.50
Return on Capital Employed	-0.31

COM:INOVIO

INOVIO Pharmaceuticals

Last Close

4.06

22/11 21:00

Market Cap

240.45M

Beta: -

Volume Today

292.77K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	0.47
P/B Ratio	9.60
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	472.27
EV Multiple	-0.65

Metric
Days Sales Outstanding	916.29
Days Payables Outstanding	47.22
Days Inventory Outstanding
Operating Cycle	6.39K
Cash Conversion Cycle	6.39K
Asset Turnover	0.01

Metric
Operating Cash Flow	-124.37M
Free Cash Flow	-124.69M
Cash Flow to Debt	-0.01
Operating Cash Flow/Sales	-0.91
Free Cash Flow Yield	-1.27

Metric
Cash & Equivalents	14.31M
Accounts Receivable	9.33M
Inventory
Goodwill
Debt to Capitalization	0.99
Debt to Assets	0.15
Current Ratio	4.00
Quick Ratio	4.77

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	16.17
R&D to Revenue	130.61
SG&A to Revenue	60.06